More Time For EU Nitrosamine Evaluations Due To COVID-19
Companies Are Allowed Additional Six Months
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.
